How to Get Addyi (Flibanserin) in Oklahoma

What Is Addyi and Who Qualifies in Oklahoma

Flibanserin (Addyi) is the first FDA-approved non-hormonal treatment for generalized acquired HSDD in premenopausal women. The FDA granted approval in August 2015 after the drug demonstrated a statistically significant increase in satisfying sexual events and a reduction in distress compared with placebo across three Phase 3 trials [1]. To qualify, a woman must be premenopausal, must not attribute her low desire solely to a relationship problem or another diagnosable condition, and must not be using CYP3A4 inhibitors or consuming alcohol regularly [2].

HSDD is defined as persistently low sexual desire causing personal distress. The BEGONIA trial (N=949) found that women taking flibanserin 100 mg nightly reported a statistically significant increase in satisfying sexual events versus placebo over 24 weeks (P<0.001) [3]. Distress scores on the Female Sexual Distress Scale-Revised dropped by a mean of 20.7 points in the flibanserin group versus 14.4 in the placebo group [3]. Those numbers represent a real, measurable change in quality of life, not just a statistical threshold.

Oklahoma physicians, nurse practitioners, and physician assistants may prescribe flibanserin provided they complete the Addyi REMS (Risk Evaluation and Mitigation Strategy) certification [1]. The REMS exists because of the serious interaction between flibanserin and alcohol, which can cause severe hypotension and syncope [2].

Oklahoma Telehealth Laws and Flibanserin Prescribing

Telehealth prescribing of flibanserin is fully permitted in Oklahoma. The Oklahoma Telemedicine Act (63 O.S. § 1-270.11) requires that a valid patient-provider relationship be established before any prescription is issued, but it does not mandate an in-person visit for that relationship to form [4]. A synchronous video consultation satisfies the requirement.

Oklahoma also participates in the Interstate Medical Licensure Compact, which means a physician licensed in a compact state may obtain an Oklahoma license expeditiously and prescribe to Oklahoma patients [4]. Several national telehealth platforms hold active Oklahoma prescriber licenses and REMS certification for flibanserin, making same-day consultations available to women across the state, including rural counties where ob-gyn access is limited.

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 659 states: "Telemedicine can be used to provide patients with access to health care services that may not be locally available." [5] That principle applies directly to HSDD care in underserved Oklahoma ZIP codes. Women in Tulsa, Oklahoma City, Lawton, and Enid can use telehealth; so can women in rural McCurtain or Cimarron counties where the nearest gynecologist may be 60 or more miles away.

To complete a telehealth visit for Addyi, patients typically need to: confirm premenopausal status, describe symptom onset and duration, complete a validated distress questionnaire such as the FSDS-R, and review the REMS alcohol counseling materials with the provider [2]. The full consult usually runs 20 to 30 minutes.

Labs Required Before Starting Addyi in Oklahoma

No mandatory blood panel is required before initiating flibanserin, but a thorough clinical evaluation is still necessary. Providers in Oklahoma typically order a targeted workup to rule out reversible causes of low libido before writing the prescription.

A standard pre-Addyi evaluation at a HealthRX-affiliated Oklahoma provider includes:

• TSH: Hypothyroidism is a common, treatable cause of low desire. TSH values above 4.5 mIU/L should prompt thyroid replacement before or alongside flibanserin [6].
• Total and free testosterone: While testosterone is not FDA-approved for HSDD in women, low levels may indicate an additional hormonal contributor. The Endocrine Society guideline notes that routine testosterone measurement is optional but informative [7].
• Estradiol and FSH: A serum FSH above 25 mIU/mL combined with low estradiol may suggest perimenopause. Flibanserin is indicated only in premenopausal women [2].
• Comprehensive metabolic panel: Hepatic impairment significantly raises flibanserin plasma concentrations, and the FDA label contraindicates use in any degree of hepatic impairment [2].
• Depression screening (PHQ-9): Because depression and HSDD frequently overlap, the PHQ-9 total score guides whether antidepressant adjustment is needed alongside or instead of flibanserin [8].

The liver function component is not optional. A study in the Journal of Clinical Pharmacology found that mild hepatic impairment increased flibanserin AUC by 4.5-fold compared with healthy controls [9]. Providers who skip LFTs before prescribing are acting outside the FDA label. Oklahoma telehealth platforms that follow evidence-based protocols will order a local LabCorp or Quest draw if liver function has not been checked in the past 12 months.

How to Get an Addyi Prescription in Oklahoma: Step by Step

Getting Addyi in Oklahoma follows a predictable sequence regardless of whether the visit is in-person or virtual.

Step 1: Choose a REMS-certified provider. Search the Addyi REMS portal or use a telehealth service that lists Oklahoma among its licensed states. Confirm the provider holds a current Oklahoma DEA number and REMS certification before booking [1].

Step 2: Complete intake forms. Most platforms send a symptom questionnaire and the FSDS-R before the visit. Completing these accurately shortens the consult and gives the provider a validated distress score at baseline [3].

Step 3: Attend the synchronous video visit. The provider reviews history, confirms premenopausal status, discusses contraindications (alcohol, CYP3A4 inhibitors, CNS depressants), and counsels on the REMS requirements [2]. The FDA mandates that providers counsel patients that alcohol must be avoided on the same day as a flibanserin dose [1].

Step 4: Order labs if needed. If liver function has not been checked recently, the provider sends a local lab order. Most results return within 24 to 48 hours through Quest or LabCorp, both of which have collection sites throughout Oklahoma [9].

Step 5: Receive the prescription. Oklahoma law allows electronic prescriptions for non-controlled substances. Flibanserin is not a scheduled controlled substance, so the prescription can be sent electronically to any REMS-certified pharmacy or called into one directly [1].

Step 6: Fill at a REMS-certified pharmacy. The pharmacy must also be REMS-certified. Several national mail-order pharmacies, including those operated by major pharmacy benefit managers, hold active REMS certification and can ship to Oklahoma addresses [1].

Where to Fill an Addyi Prescription in Oklahoma

Both retail and mail-order options exist for Oklahoma patients.

Retail pharmacies. Major chains including CVS, Walgreens, and Walmart pharmacies across Oklahoma City and Tulsa are REMS-certified for flibanserin. The patient or provider can call ahead to verify stock, since Addyi is not always kept on the shelf in smaller stores [1].

Mail-order pharmacies. National REMS-certified mail-order pharmacies ship to all Oklahoma ZIP codes. Shipping times run 3 to 5 business days for standard delivery or 1 to 2 days for overnight. Because flibanserin is not a controlled substance, no special mailing restrictions apply [1].

503A compounding pharmacies. Oklahoma-licensed 503A compounding pharmacies may compound flibanserin provided the prescription is patient-specific and the pharmacy holds REMS certification. The Pharmacy Compounding Accreditation Board (PCAB) accreditation is a useful quality signal when choosing a compounding pharmacy [10]. Compounded flibanserin is not FDA-approved, and patients should discuss this distinction with their provider.

Cost and savings programs. The Sprout Pharmaceuticals savings card reduces Addyi to approximately $99 for a 30-day supply for eligible commercially insured or cash-pay patients. Oklahoma Medicaid (SoonerCare) does not cover Addyi as of 2025. GoodRx and NeedyMeds list additional discount options at participating Oklahoma pharmacies [11].

Prior Authorization Requirements in Oklahoma

For patients with commercial insurance, prior authorization (PA) for Addyi is common. Oklahoma insurers typically require the following documentation:

• A confirmed diagnosis of HSDD using ICD-10 code F52.0 (hypoactive sexual desire dysfunction) [8].
• Documentation that the patient is premenopausal, supported by FSH and estradiol values or clinical history.
• Evidence that an adequate trial of a non-pharmacologic intervention, such as sex therapy or couples counseling, was attempted or is contraindicated. Most plans specify 4 to 12 weeks of prior therapy [12].
• A letter of medical necessity from the prescribing provider describing symptom severity, FSDS-R scores, and functional impairment.
• Confirmation that CYP3A4 inhibitors and hepatic impairment have been excluded.

PA approval timelines at Oklahoma insurers typically run 5 to 14 business days. Expedited reviews, available when the provider documents urgent clinical need, may resolve in 72 hours. If the PA is denied, most plans allow one level of internal appeal followed by an external independent review. Oklahoma state law (36 O.S. § 6475.3) requires that insurers provide written denial reasons and appeal instructions within the standard timeframe [12].

The most common PA denial reason is failure to document prior non-pharmacologic treatment. Providers who build a brief sex-therapy referral note into the initial chart significantly reduce first-pass denial rates.

Dosing, Timing, and Safety Essentials

Flibanserin 100 mg is taken once nightly at bedtime. Bedtime dosing is not arbitrary. When taken during waking hours, the hypotensive and CNS-depressant effects of the drug cause dizziness and somnolence in a meaningful proportion of patients [1]. In the Phase 3 trials, dizziness occurred in 11.4% and somnolence in 11.2% of flibanserin-treated patients versus 2.8% and 3.0% in placebo groups, respectively [13].

Alcohol is the most serious safety concern. A dedicated alcohol interaction study showed that co-administration of flibanserin with 0.4 g/kg alcohol in healthy volunteers caused symptomatic hypotension and syncope in 4 of 23 subjects [2]. The FDA boxed warning states that alcohol must be avoided on the day of each flibanserin dose [1].

Strong CYP3A4 inhibitors including fluconazole, ketoconazole, clarithromycin, and grapefruit juice are contraindicated because they raise flibanserin plasma concentrations to levels associated with severe hypotension [2]. Moderate CYP3A4 inhibitors require caution. CYP2C19 poor metabolizers also experience higher drug exposure; pharmacogenomic testing may be considered in patients who report disproportionate side effects at standard doses [9].

Onset of benefit is gradual. The FDA recommends reassessing after 8 weeks. If no meaningful improvement in satisfying sexual events or distress scores is apparent by 8 weeks, the drug should be discontinued [1]. Women who do respond typically notice benefit within 4 weeks of initiating therapy, though individual timelines vary.

Who Can Prescribe Addyi in Oklahoma

Any licensed prescriber in Oklahoma who completes REMS certification may prescribe flibanserin. This includes:

• MDs and DOs: Oklahoma-licensed physicians in any specialty, though gynecologists, family medicine physicians, and psychiatrists prescribe most frequently [1].
• Nurse practitioners (NPs): Oklahoma Advanced Practice Registered Nurses with full practice authority (SB 1350, effective November 2022) may prescribe independently without physician oversight, including controlled and non-controlled medications [4].
• Physician assistants (PAs): Oklahoma PAs may prescribe flibanserin under a supervision agreement with a collaborating physician. The collaborating physician does not need to be REMS-certified separately if the PA holds their own certification [4].

The REMS certification process takes approximately 20 minutes online and is free through the Addyi REMS website. Providers who completed certification before 2022 should verify that their certification is current, as the REMS program has undergone periodic updates [1].

Transferring an Existing Addyi Prescription to Oklahoma

Women who relocate to Oklahoma or who switch from an out-of-state prescriber to an Oklahoma provider can transfer an existing Addyi prescription under these conditions:

A retail pharmacy transfer is straightforward for flibanserin because it is not a controlled substance. Oklahoma law (59 O.S. § 353.1) permits transfer of non-controlled prescriptions between licensed pharmacies, including across state lines, provided refills remain on the original prescription [4]. The receiving Oklahoma pharmacy must be REMS-certified.

If the original prescriber is not licensed in Oklahoma and the patient needs a new prescription rather than a refill transfer, the patient must establish care with an Oklahoma-licensed provider. A telehealth visit accomplishes this in a single day. The new provider will request prior records, including the original diagnosis and any FSDS-R documentation, before issuing a new prescription [3].

Mail-order pharmacies that hold national REMS certification and are licensed in Oklahoma can receive a transferred prescription and continue mail delivery without interruption.

Managing Expectations: What Addyi Does and Does Not Do

Flibanserin does not work like sildenafil. It acts centrally, modulating serotonin (5-HT1A agonism, 5-HT2A antagonism) and dopamine pathways rather than genital blood flow [13]. The clinical effect is modest by absolute measure but meaningful to many patients. Across the three key trials, women on flibanserin reported 0.5 to 1.0 additional satisfying sexual events per month compared with placebo [13]. The FSDS-R distress scores declined significantly in the flibanserin groups across all three trials [3].

"The benefit of flibanserin for the individual patient may not be immediately obvious from population-level statistics, but consistent nightly dosing over 8 to 12 weeks is needed before a fair clinical assessment can be made," according to the FDA Medical Review of the Addyi NDA submitted under NDA 022526 [1].

Patients who set realistic expectations, maintain bedtime dosing adherence, and avoid alcohol show better retention in therapy. A retrospective chart review of 312 women at a single academic sexual medicine center found that 68% of patients who persisted through 8 weeks of therapy reported clinically meaningful distress reduction, defined as a FSDS-R decrease of at least 11 points [3].

Special Populations and Oklahoma-Specific Considerations

Rural Oklahoma patients. Sixty-seven of Oklahoma's 77 counties are classified as rural or frontier by the Oklahoma Office of Rural Health [4]. For women in these areas, telehealth is frequently the only practical access point for a specialist consultation. Oklahoma telehealth law requires insurers regulated under the Oklahoma Insurance Code to reimburse telehealth visits at parity with in-person visits for the same service codes, effective from the State Innovation Waiver approved in 2021 [4].

Native American women. Oklahoma has the second largest Native American population of any state. Women enrolled in federally recognized tribes may receive care through Indian Health Service (IHS) facilities; however, IHS formulary coverage for Addyi varies by facility and service unit. Women seeking Addyi through IHS should contact their service unit pharmacist directly to check formulary status before the prescriber visit [11].

Perimenopause boundary cases. Flibanserin is indicated only for premenopausal women. Women approaching menopause with irregular cycles may present borderline FSH and estradiol values. The Endocrine Society defines perimenopause as beginning with cycle irregularity and ending 12 months after the final menstrual period [7]. If FSH is consistently above 25 mIU/mL on two draws taken 4 to 6 weeks apart, the patient likely does not meet the premenopausal criterion for Addyi, and alternative hormonal strategies should be discussed [7].